Johns Hopkins ABX Guide
Bezlotoxumab
To view the entire topic, please log in or purchase a subscription.
Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
Reduce the recurrence of Clostridium difficile infections (CDIs) in patients 18 years of age and older who are receiving antibacterial CDI drug treatment and are at high risk for CDI recurrence.
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
Reduce the recurrence of Clostridium difficile infections (CDIs) in patients 18 years of age and older who are receiving antibacterial CDI drug treatment and are at high risk for CDI recurrence.
There's more to see -- the rest of this topic is available only to subscribers.
